secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019889
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q1 revenue down 41% to $176K; operating loss $9.3M; Bio-Rad partnership
--------------------------------------------------------------------------------

- Net revenue $176K, down 41% YoY; operating loss $9.3M (incl. $3.3M contingent consideration loss) vs income $5.9M in Q1 2023.
- Cash burn reduced to $3.9M in Q1; management targets average quarterly burn below $5M.
- Announced global commercialization partnership with Bio-Rad; Bio-Rad also bought 8.99% stake via $15.8M equity private placement.
- On track to ship RUO GraftAssure kits to initial customers in Asia, US, and EU during Q2 2024; IVD kit under development for FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/0001493152-24-019889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer